U.S. Markets closed
  • S&P Futures

    3,739.00
    -5.25 (-0.14%)
     
  • Dow Futures

    30,197.00
    +8.00 (+0.03%)
     
  • Nasdaq Futures

    13,063.00
    -42.50 (-0.32%)
     
  • Russell 2000 Futures

    2,104.80
    +0.50 (+0.02%)
     
  • Crude Oil

    52.63
    -0.22 (-0.42%)
     
  • Gold

    1,834.30
    -10.60 (-0.57%)
     
  • Silver

    25.12
    -0.26 (-1.04%)
     
  • EUR/USD

    1.2098
    -0.0013 (-0.1089%)
     
  • 10-Yr Bond

    1.0140
    -0.0260 (-2.50%)
     
  • Vix

    37.21
    +14.19 (+61.64%)
     
  • GBP/USD

    1.3662
    -0.0029 (-0.2118%)
     
  • USD/JPY

    104.3600
    +0.2880 (+0.2767%)
     
  • BTC-USD

    31,099.33
    -1,020.29 (-3.18%)
     
  • CMC Crypto 200

    625.63
    -14.29 (-2.23%)
     
  • FTSE 100

    6,567.37
    -86.64 (-1.30%)
     
  • Nikkei 225

    28,323.06
    -312.15 (-1.09%)
     

Penumbra Class Action Reminder

Newsfile Corp.
·2 min read

Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Penumbra To Contact Him Directly To Discuss Their Options

New York, New York--(Newsfile Corp. - December 24, 2020) - Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Penumbra, Inc. ("Penumbra" or the "Company") (NYSE: PEN).

If you suffered losses exceeding $50,000 investing in Penumbra stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/PEN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).



There is no cost or obligation to you.



On November 10, 2020, Quintessential Capital Management issued a research report on Penumbra entitled "Penumbra and its 'Killer Catheter': A tale of corporate greed and seemingly blatant disregard for patients' lives[.]"

Then, on December 8, 2020, Quintessential Capital Management released a follow-up research report entitled "Is Penumbra's core scientific research authored by a fake person?: The incredible story of Penumbra's Dr. Antik Bose[.]" The report alleged that some of the Company's scientific research appear to have been incorrectly credited or even authored by a fake individual.

On the news of the report, Penumbra's stock price fell $19.95 per share, or 8.91%, to close at $204.07 per share on December 8, 2020.

Then, on December 15, 2020, after the market, Penumbra announced that it was voluntarily "recalling its JET 7 Xtra Flex because the catheter may become susceptible to distal tip damage during use[, which] may result in potential vessel damage, and subsequent patient injury or death."

On this news, Penumbra's stock price fell $13.84 per share, or 7.33%, to a close of $174.98 per share on December 16, 2020.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/70982